Skip to main content
Top
Published in: BMC Infectious Diseases 1/2015

Open Access 01-12-2015 | Research article

A nationwide population-based cohort study to identify the correlation between heart failure and the subsequent risk of herpes zoster

Authors: Ping-Hsun Wu, Yi-Ting Lin, Chun-Yi Lin, Ming-Yii Huang, Wei-Chiao Chang, Wei-Pin Chang

Published in: BMC Infectious Diseases | Issue 1/2015

Login to get access

Abstract

Background

The association between heart failure (HF) and herpes zoster has rarely been studied. We investigated the hypothesis that HF may increase the risk of herpes zoster in Taiwan using a nationwide Taiwanese population-based claims database.

Method

Our study cohort consisted of patients who received a diagnosis of HF in 2001 ~ 2009 (N = 4785). For a comparison cohort, three age- and gender-matched control patients for every patient in the study cohort were selected using random sampling (N = 14,355). All subjects were tracked for 1 year from the date of cohort entry to identify whether or not they had developed herpes zoster. Cox proportional-hazard regressions were performed to evaluate 1-year herpes zoster-free survival rates.

Results

The main finding of this study was that patients with HF seemed to be at an increased risk of developing herpes zoster. Of the total patients, 211 patients developed herpes zoster during the 1-year follow-up period, among whom 83 were HF patients and 128 were in the comparison cohort. The adjusted hazard ratio (AHR) of herpes zoster in patients with HF was higher (AHR: 2.07; 95% confidence interval (CI): 1.54 ~ 2.78; p < 0.001) than that of the controls during the 1-year follow-up. Our study also investigated whether HF is a gender-dependent risk factor for herpes zoster. We found that male patients with HF had an increased risk of developing herpes zoster (AHR: 2.30 95% CI: 1.51 ~ 3.50; p < 0.001).

Conclusions

The findings of our population-based study suggest that patients with HF may have an increased risk of herpes zoster. These health associations should be taken into consideration, and further studies should focused on the cost-effectiveness of the herpes zoster vaccine should be designed for HF patients.
Literature
1.
go back to reference Jih JS, Chen YJ, Lin MW, Chen YC, Chen TJ, Huang YL, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol. 2009;89(6):612–6.CrossRefPubMed Jih JS, Chen YJ, Lin MW, Chen YC, Chen TJ, Huang YL, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol. 2009;89(6):612–6.CrossRefPubMed
2.
go back to reference Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med. 2000;342(9):635–45.CrossRefPubMed Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med. 2000;342(9):635–45.CrossRefPubMed
3.
go back to reference Lin HC, Chien CW, Ho JD. Herpes zoster ophthalmicus and the risk of stroke: a population-based follow-up study. Neurology. 2010;74(10):792–7.CrossRefPubMed Lin HC, Chien CW, Ho JD. Herpes zoster ophthalmicus and the risk of stroke: a population-based follow-up study. Neurology. 2010;74(10):792–7.CrossRefPubMed
4.
go back to reference Kang JH, Ho JD, Chen YH, Lin HC. Increased risk of stroke after a herpes zoster attack: a population-based follow-up study. Stroke. 2009;40(11):3443–8.CrossRefPubMed Kang JH, Ho JD, Chen YH, Lin HC. Increased risk of stroke after a herpes zoster attack: a population-based follow-up study. Stroke. 2009;40(11):3443–8.CrossRefPubMed
5.
go back to reference Ho JD, Xirasagar S, Lin HC. Increased risk of a cancer diagnosis after herpes zoster ophthalmicus: a nationwide population-based study. Ophthalmology. 2011;118(6):1076–81.CrossRefPubMed Ho JD, Xirasagar S, Lin HC. Increased risk of a cancer diagnosis after herpes zoster ophthalmicus: a nationwide population-based study. Ophthalmology. 2011;118(6):1076–81.CrossRefPubMed
8.
go back to reference Liesegang TJ. Herpes zoster virus infection. Curr Opin Opthalmol. 2004;15(6):531–6.CrossRef Liesegang TJ. Herpes zoster virus infection. Curr Opin Opthalmol. 2004;15(6):531–6.CrossRef
9.
go back to reference Bowsher D. The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: A retrospective survey in an elderly population. Eur J Pain. 1999;3(4):335–42.CrossRefPubMed Bowsher D. The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: A retrospective survey in an elderly population. Eur J Pain. 1999;3(4):335–42.CrossRefPubMed
10.
go back to reference Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127(2):305–14.CrossRefPubMedPubMedCentral Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127(2):305–14.CrossRefPubMedPubMedCentral
11.
go back to reference Lin YH, Huang LM, Chang IS, Tsai FY, Lu CY, Shao PL, et al. Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine. 2010;28(5):1217–20.CrossRefPubMed Lin YH, Huang LM, Chang IS, Tsai FY, Lu CY, Shao PL, et al. Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine. 2010;28(5):1217–20.CrossRefPubMed
12.
go back to reference Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med. 1995;155(15):1605–9.CrossRefPubMed Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med. 1995;155(15):1605–9.CrossRefPubMed
13.
go back to reference Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clinic Proceedings Mayo Clinic. 2007;82(11):1341–9.CrossRef Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clinic Proceedings Mayo Clinic. 2007;82(11):1341–9.CrossRef
14.
go back to reference Schmader K, George LK, Burchett BM, Pieper CF. Racial and psychosocial risk factors for herpes zoster in the elderly. J Infect Dis. 1998;178 Suppl 1:S67–70.CrossRefPubMed Schmader K, George LK, Burchett BM, Pieper CF. Racial and psychosocial risk factors for herpes zoster in the elderly. J Infect Dis. 1998;178 Suppl 1:S67–70.CrossRefPubMed
15.
go back to reference Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, et al. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection. 2008;36(3):226–30.CrossRefPubMed Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, et al. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection. 2008;36(3):226–30.CrossRefPubMed
17.
go back to reference Gilden DH, Cohrs RJ, Mahalingam R. Clinical and molecular pathogenesis of varicella virus infection. Viral Immunol. 2003;16(3):243–58.CrossRefPubMed Gilden DH, Cohrs RJ, Mahalingam R. Clinical and molecular pathogenesis of varicella virus infection. Viral Immunol. 2003;16(3):243–58.CrossRefPubMed
18.
go back to reference Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neurol Clin. 2008;26(3):675–97. viii.CrossRefPubMedPubMedCentral Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neurol Clin. 2008;26(3):675–97. viii.CrossRefPubMedPubMedCentral
19.
go back to reference Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007;57(8):1431–8.CrossRefPubMed Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007;57(8):1431–8.CrossRefPubMed
20.
go back to reference Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4(1):26–33.CrossRefPubMed Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4(1):26–33.CrossRefPubMed
21.
go back to reference Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford). 2006;45(11):1370–5.CrossRef Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford). 2006;45(11):1370–5.CrossRef
22.
go back to reference McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009;48(10):1364–71.CrossRefPubMedPubMedCentral McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009;48(10):1364–71.CrossRefPubMedPubMedCentral
23.
go back to reference Wung PK, Holbrook JT, Hoffman GS, Tibbs AK, Specks U, Min YI, et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med. 2005;118(12):1416.CrossRefPubMed Wung PK, Holbrook JT, Hoffman GS, Tibbs AK, Specks U, Min YI, et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med. 2005;118(12):1416.CrossRefPubMed
24.
go back to reference Chen HH, Chen YM, Chen TJ, Lan JL, Lin CH, Chen DY. Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort. Clinics (Sao Paulo). 2011;66(7):1177–82.CrossRef Chen HH, Chen YM, Chen TJ, Lan JL, Lin CH, Chen DY. Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort. Clinics (Sao Paulo). 2011;66(7):1177–82.CrossRef
25.
go back to reference Yang YW, Chen YH, Wang KH, Wang CY, Lin HW. Risk of herpes zoster among patients with chronic obstructive pulmonary disease: a population-based study. Can Med Assoc. 2011;183(5):E275–80.CrossRef Yang YW, Chen YH, Wang KH, Wang CY, Lin HW. Risk of herpes zoster among patients with chronic obstructive pulmonary disease: a population-based study. Can Med Assoc. 2011;183(5):E275–80.CrossRef
26.
27.
go back to reference Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis. 2003;188(9):1336–44.CrossRefPubMed Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis. 2003;188(9):1336–44.CrossRefPubMed
28.
go back to reference Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292(3):344–50.CrossRefPubMed Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292(3):344–50.CrossRefPubMed
29.
go back to reference Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, Psaty BM, Smith NL, Newman AB, et al. Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study. Arch Intern Med. 2009;169(7):708–15.CrossRefPubMedPubMedCentral Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, Psaty BM, Smith NL, Newman AB, et al. Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study. Arch Intern Med. 2009;169(7):708–15.CrossRefPubMedPubMedCentral
30.
31.
go back to reference Hata A, Kuniyoshi M, Ohkusa Y. Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection. 2011;39(6):537–44.CrossRefPubMedPubMedCentral Hata A, Kuniyoshi M, Ohkusa Y. Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection. 2011;39(6):537–44.CrossRefPubMedPubMedCentral
32.
go back to reference Kiecolt-Glaser JK, Glaser R. Psychoneuroimmunology and health consequences: data and shared mechanisms. Psychosom Med. 1995;57(3):269–74.CrossRefPubMed Kiecolt-Glaser JK, Glaser R. Psychoneuroimmunology and health consequences: data and shared mechanisms. Psychosom Med. 1995;57(3):269–74.CrossRefPubMed
33.
go back to reference Irwin M, Costlow C, Williams H, Artin KH, Chan CY, Stinson DL, et al. Cellular immunity to varicella-zoster virus in patients with major depression. J Infect Dis. 1998;178 Suppl 1:S104–8.CrossRefPubMed Irwin M, Costlow C, Williams H, Artin KH, Chan CY, Stinson DL, et al. Cellular immunity to varicella-zoster virus in patients with major depression. J Infect Dis. 1998;178 Suppl 1:S104–8.CrossRefPubMed
34.
go back to reference Moser DK, Worster PL. Effect of psychosocial factors on physiologic outcomes in patients with heart failure. J Cardiovasc Nurs. 2000;14(4):106–15.CrossRefPubMed Moser DK, Worster PL. Effect of psychosocial factors on physiologic outcomes in patients with heart failure. J Cardiovasc Nurs. 2000;14(4):106–15.CrossRefPubMed
35.
go back to reference Piano MR, Kim SD, Jarvis C. Cellular events linked to cardiac remodeling in heart failure: targets for pharmacologic intervention. J Cardiovasc Nurs. 2000;14(4):1–23. quiz 119–120.CrossRefPubMed Piano MR, Kim SD, Jarvis C. Cellular events linked to cardiac remodeling in heart failure: targets for pharmacologic intervention. J Cardiovasc Nurs. 2000;14(4):1–23. quiz 119–120.CrossRefPubMed
36.
go back to reference Vredevoe DL, Widawski M, Fonarow GC, Hamilton M, Martinez-Maza O, Gage JR. Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure. Am J Cardiol. 2004;93(8):1007–11.CrossRefPubMed Vredevoe DL, Widawski M, Fonarow GC, Hamilton M, Martinez-Maza O, Gage JR. Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure. Am J Cardiol. 2004;93(8):1007–11.CrossRefPubMed
37.
go back to reference Odom CI, Gaston DC, Markert JM, Cassady KA. Human herpesviridae methods of natural killer cell evasion. Advance Virol. 2012;2012:359869. Odom CI, Gaston DC, Markert JM, Cassady KA. Human herpesviridae methods of natural killer cell evasion. Advance Virol. 2012;2012:359869.
38.
go back to reference Yawn BP, Itzler RF, Wollan PC, Pellissier JM, Sy LS, Saddier P. Health care utilization and cost burden of herpes zoster in a community population. Mayo Clinic Proceedings Mayo Clinic. 2009;84(9):787–94.CrossRef Yawn BP, Itzler RF, Wollan PC, Pellissier JM, Sy LS, Saddier P. Health care utilization and cost burden of herpes zoster in a community population. Mayo Clinic Proceedings Mayo Clinic. 2009;84(9):787–94.CrossRef
39.
go back to reference Cotton SJ, Belcher J, Rose P, Jagadeesan KS, Neal RD. The risk of a subsequent cancer diagnosis after herpes zoster infection: primary care database study. Br J Cancer. 2013;108(3):721–6.CrossRefPubMedPubMedCentral Cotton SJ, Belcher J, Rose P, Jagadeesan KS, Neal RD. The risk of a subsequent cancer diagnosis after herpes zoster infection: primary care database study. Br J Cancer. 2013;108(3):721–6.CrossRefPubMedPubMedCentral
40.
go back to reference Iglar K, Kopp A, Glazier RH. Herpes zoster as a marker of underlying malignancy. Open J Med. 2013;7(2):e68–73. Iglar K, Kopp A, Glazier RH. Herpes zoster as a marker of underlying malignancy. Open J Med. 2013;7(2):e68–73.
41.
go back to reference Buntinx F, Wachana R, Bartholomeeusen S, Sweldens K, Geys H. Is herpes zoster a marker for occult or subsequent malignancy? Br J Gen Pract. 2005;55(511):102–7.PubMedPubMedCentral Buntinx F, Wachana R, Bartholomeeusen S, Sweldens K, Geys H. Is herpes zoster a marker for occult or subsequent malignancy? Br J Gen Pract. 2005;55(511):102–7.PubMedPubMedCentral
42.
go back to reference Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.CrossRefPubMed Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.CrossRefPubMed
43.
go back to reference Svanstrom H, Pasternak B, Hviid A. Association of treatment with losartan vs candesartan and mortality among patients with heart failure. JAMA. 2012;307(14):1506–12.CrossRefPubMed Svanstrom H, Pasternak B, Hviid A. Association of treatment with losartan vs candesartan and mortality among patients with heart failure. JAMA. 2012;307(14):1506–12.CrossRefPubMed
Metadata
Title
A nationwide population-based cohort study to identify the correlation between heart failure and the subsequent risk of herpes zoster
Authors
Ping-Hsun Wu
Yi-Ting Lin
Chun-Yi Lin
Ming-Yii Huang
Wei-Chiao Chang
Wei-Pin Chang
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2015
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-015-0747-9

Other articles of this Issue 1/2015

BMC Infectious Diseases 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.